210 related articles for article (PubMed ID: 8624271)
21. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.
Browman GP; Bergsagel D; Sicheri D; O'Reilly S; Wilson KS; Rubin S; Belch A; Shustik C; Barr R; Walker I
J Clin Oncol; 1995 Sep; 13(9):2354-60. PubMed ID: 7666094
[TBL] [Abstract][Full Text] [Related]
22. A new staging system for multiple myeloma based on the number of S-phase plasma cells.
San Miguel JF; García-Sanz R; González M; Moro MJ; Hernández JM; Ortega F; Borrego D; Carnero M; Casanova F; Jiménez R
Blood; 1995 Jan; 85(2):448-55. PubMed ID: 7811998
[TBL] [Abstract][Full Text] [Related]
23. Peptichemio in multiple myeloma. (Preliminary results).
Cavo M; Gobbi M; Tura S
Haematologica; 1981 Apr; 66(2):208-15. PubMed ID: 6791997
[No Abstract] [Full Text] [Related]
24. Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma--a retrospective population based study of 1162 patients.
Lund J; Uttervall K; Liwing J; Gahrton G; Alici E; Aschan J; Holmberg E; Nahi H
Eur J Haematol; 2014 Jan; 92(1):19-25. PubMed ID: 24118547
[TBL] [Abstract][Full Text] [Related]
25. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
[TBL] [Abstract][Full Text] [Related]
26. An update of two randomized trials in previously untreated multiple myeloma comparing melphalan and prednisone versus three- and five-drug combinations: an Argentine Group for the Treatment of Acute Leukemia Study.
Pavlovsky S; Corrado C; Santarelli MT; Saslavsky J; Cavagnaro F; Palau M; de Tezanos Pinto M; Huberman A; Lein JM
J Clin Oncol; 1988 May; 6(5):769-75. PubMed ID: 3284974
[TBL] [Abstract][Full Text] [Related]
27. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
Mateos MV; Richardson PG; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Schots R; Jiang B; Esseltine DL; Liu K; Cakana A; van de Velde H; San Miguel JF
J Clin Oncol; 2010 May; 28(13):2259-66. PubMed ID: 20368561
[TBL] [Abstract][Full Text] [Related]
28. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
Beksac M; Haznedar R; Firatli-Tuglular T; Ozdogu H; Aydogdu I; Konuk N; Sucak G; Kaygusuz I; Karakus S; Kaya E; Ali R; Gulbas Z; Ozet G; Goker H; Undar L
Eur J Haematol; 2011 Jan; 86(1):16-22. PubMed ID: 20942865
[TBL] [Abstract][Full Text] [Related]
29. Clinical staging and therapeutic results in multiple myeloma.
Santoro A; Schieppati G; Franchi F; Valagussa P; Monfardini S
Eur J Cancer Clin Oncol; 1983 Oct; 19(10):1353-9. PubMed ID: 6685627
[TBL] [Abstract][Full Text] [Related]
30. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated.
Bladé J; San Miguel JF; Fontanillas M; Alcalá A; Maldonado J; García-Conde J; Conde E; Conzález-Brito G; Moro MJ; Escudero ML; Trujillo J; Pascual A; Rozman C; Estapé J; Montserrat E
J Clin Oncol; 1996 Jul; 14(7):2167-73. PubMed ID: 8683251
[TBL] [Abstract][Full Text] [Related]
31. Proliferative activity, response to therapy and survival in multiple myeloma.
Riccardi A; Montecucco C; Merlini G; Ucci G; Cremonini N; Gobbi PG; Ascari E
Haematologica; 1984; 69(2):148-62. PubMed ID: 6429002
[No Abstract] [Full Text] [Related]
32. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
[TBL] [Abstract][Full Text] [Related]
33. Classification and prognostic evaluation in multiple myeloma. A retrospective study of relationship of survivals and responses to chemotherapy to immunological types, 20 single prognostic factors, 15 clinical staging systems, and 6 morphological classifications.
Pasqualetti P; Colantonio D; Collacciani A; Casale R; Natali G
Panminerva Med; 1991; 33(2):93-110. PubMed ID: 1923560
[TBL] [Abstract][Full Text] [Related]
34. Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults.
MacLennan IC; Cusick J
Br J Cancer; 1985 Aug; 52(2):153-8. PubMed ID: 3896288
[TBL] [Abstract][Full Text] [Related]
35. Peptichemio induction therapy in myelomatosis.
Merlini G; Gobbi PG; Riccardi A; Riva G; Sardi C; Perugini S
Cancer Chemother Pharmacol; 1982; 8(1):9-16. PubMed ID: 7094202
[TBL] [Abstract][Full Text] [Related]
36. Combination chemotherapy for multiple myeloma with BCNU, cyclophosphamide, vincristine, melphalan, and prednisone (M-2 protocol).
Case DC; Sonneborn HL; Paul SD; Hayes DM; Dorsk BM; Carroll RJ; Bove L
Oncology; 1985; 42(3):137-40. PubMed ID: 3858763
[TBL] [Abstract][Full Text] [Related]
37. Remission maintenance therapy for multiple myeloma.
Arch Intern Med; 1975 Jan; 135(1):147-52. PubMed ID: 1111463
[TBL] [Abstract][Full Text] [Related]
38. IgD multiple myeloma. A report of three cases.
Martini R; Santini S; Bottari G
Minerva Med; 1996 Mar; 87(3):109-12. PubMed ID: 8668286
[TBL] [Abstract][Full Text] [Related]
39. Results and further perspectives of plasmocytoma chemotherapy.
Sakalová A; Hrubisko M; Gazová S; Steruská M; Prümmerová J
Neoplasma; 1986; 33(2):251-8. PubMed ID: 3520353
[TBL] [Abstract][Full Text] [Related]
40. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
Boccadoro M; Marmont F; Tribalto M; Avvisati G; Andriani A; Barbui T; Cantonetti M; Carotenuto M; Comotti B; Dammacco F
J Clin Oncol; 1991 Mar; 9(3):444-8. PubMed ID: 1999714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
